U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C16H20N2.C4H4O4
Molecular Weight 356.4156
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of PHENIRAMINE MALEATE

SMILES

OC(=O)\C=C/C(O)=O.CN(C)CCC(C1=CC=CC=C1)C2=CC=CC=N2

InChI

InChIKey=SSOXZAQUVINQSA-BTJKTKAUSA-N
InChI=1S/C16H20N2.C4H4O4/c1-18(2)13-11-15(14-8-4-3-5-9-14)16-10-6-7-12-17-16;5-3(6)1-2-4(7)8/h3-10,12,15H,11,13H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b;2-1-

HIDE SMILES / InChI

Molecular Formula C4H4O4
Molecular Weight 116.0722
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Molecular Formula C16H20N2
Molecular Weight 240.3434
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: Description was created based on several sources, including http://www.druginfosys.com/drug.aspx?drugcode=561&type=1 | https://www.drugbank.ca/drugs/DB01620

Pheniramine is an antihistamine used to treat allergic conditions such as hay fever or urticaria. It is generally sold in combination with other medications, rather than as a stand-alone drug. Allergies are caused by an excessive type 1 hypersensitivity response of the body to allergens, mediated by inappropriate histamine signalling. By inhibiting the binding of histamine, antihistamines decrease the normal histamine response from cells, consequently decreasing allergic symptoms. Antihistamines such as pheniramine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue injury response involving histamine release. Antihistamines suppress the histamine-induced wheal (swelling) and flare (vasodilation) response by blocking the binding of histamine to its receptors on nerves, vascular smooth muscle, glandular cells, endothelium, and mast cells. They effectively exert competitive antagonism of histamine for H1-receptors. Pheniramine is marketed under the trade name Avil and Visine-A among others).

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
7.5 null [pKi]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
AVIL

Approved Use

Allergic conditions including hay fever, drug rashes, angioneurotic oedema, serum sickness, allergic conjunctivitis, food allergy etc. · Conditions of the respiratory tract that are accompanied by increased secretion, including vasomotor rhinitis and acute rhinitis. · All itching skin conditions, including neurodermatitis, eczema of any origin, lichen planus, acute and chronic urticaria, pruritis of the anus or genitals, pruritus in icterus and diabetes, radiation sickness etc. · Prevention and treatment of motion sickness. · Prevention and treatment of nausea, vomiting and vertigo due to Menière’s disease and other labyrinthine disturbances.
Palliative
Visine-A

Approved Use

Visine-A is an antihistamine/redness reliever eye drop, formerly available by prescription only, that provides temporary relief of itchy, red eyes due to pollen, ragweed, grass, animal hair and dander.
Primary
AVIL

Approved Use

Allergic conditions including hay fever, drug rashes, angioneurotic oedema, serum sickness, allergic conjunctivitis, food allergy etc. · Conditions of the respiratory tract that are accompanied by increased secretion, including vasomotor rhinitis and acute rhinitis. · All itching skin conditions, including neurodermatitis, eczema of any origin, lichen planus, acute and chronic urticaria, pruritis of the anus or genitals, pruritus in icterus and diabetes, radiation sickness etc. · Prevention and treatment of motion sickness. · Prevention and treatment of nausea, vomiting and vertigo due to Menière’s disease and other labyrinthine disturbances.
Preventing
AVIL

Approved Use

Allergic conditions including hay fever, drug rashes, angioneurotic oedema, serum sickness, allergic conjunctivitis, food allergy etc. · Conditions of the respiratory tract that are accompanied by increased secretion, including vasomotor rhinitis and acute rhinitis. · All itching skin conditions, including neurodermatitis, eczema of any origin, lichen planus, acute and chronic urticaria, pruritis of the anus or genitals, pruritus in icterus and diabetes, radiation sickness etc. · Prevention and treatment of motion sickness. · Prevention and treatment of nausea, vomiting and vertigo due to Menière’s disease and other labyrinthine disturbances.
Primary
AVIL

Approved Use

Allergic conditions including hay fever, drug rashes, angioneurotic oedema, serum sickness, allergic conjunctivitis, food allergy etc. · Conditions of the respiratory tract that are accompanied by increased secretion, including vasomotor rhinitis and acute rhinitis. · All itching skin conditions, including neurodermatitis, eczema of any origin, lichen planus, acute and chronic urticaria, pruritis of the anus or genitals, pruritus in icterus and diabetes, radiation sickness etc. · Prevention and treatment of motion sickness. · Prevention and treatment of nausea, vomiting and vertigo due to Menière’s disease and other labyrinthine disturbances.
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
274 ng/mL
30.5 mg single, oral
dose: 30.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHENIRAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
5768 ng × h/mL
30.5 mg single, oral
dose: 30.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHENIRAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
17 h
30.5 mg single, oral
dose: 30.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHENIRAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Chromatographic analysis of phenethylamine-antihistamine combinations using C8, C18 or cyano columns and micellar sodium dodecyl sulfate-pentanol mixtures.
2001 Apr
A phase II study of paclitaxel and cisplatin combination chemotherapy in recurrent or metastatic head and neck cancer.
2002 Apr
Efficacy and safety of rectal thiopental, intramuscular cocktail and rectal midazolam for sedation in children undergoing neuroimaging.
2002 Dec
Uniformly sized molecularly imprinted polymer for d-chlorpheniramine. Evaluation of retention and molecular recognition properties in an aqueous mobile phase.
2002 Mar 1
Extra- and intracellular formation of reactive oxygen species by human neutrophils in the presence of pheniramine, chlorpheniramine and brompheniramine.
2006 Dec
High risk behaviors of injection drug users registered with harm reduction programme in Karachi, Pakistan.
2007 Feb 10
Chiral separation of alkylamine antihistamines in pharmaceuticals by capillary isotachophoresis with charged cyclodextrin.
2007 Nov
[Toxic epidermal necrolysis following dorzolamide eyedrops].
2008 Jan
Techniques of skin biopsy and practical considerations.
2008 Jul
Pheniramines and oxidative burst of blood phagocytes during ischaemia/reperfusion.
2009 Apr
Protective effect of pheniramines against mesenteric ischaemia/reperfusion-induced injury.
2009 Apr
In vitro antibacterial activity of some systemic and topical antihistaminic preparations.
2009 Dec 1
Preparation and evaluation of orodispersible tablets of pheniramine maleate by effervescent method.
2009 Mar
Simultaneous determination of pseudoephdrine, pheniramine, guaifenisin, pyrilamine, chlorpheniramine and dextromethorphan in cough and cold medicines by high performance liquid chromatography.
2009 May 15
Halogenation effects of pheniramines on the complexation with beta-cyclodextrin.
2009 Oct 15
Substance use and addiction research in India.
2010 Jan
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Could also be used topically https://www.drugs.com/drp/pheniramine-maleate.html
Each Avil (Pheniramine maleate) tablet contains 45.3mg pheniramine maleate. In adults and children over 10 years of age, treatment is commenced with half a tablet taken up to three times daily. This dose may be increased to one tablet taken up to three times daily if required. Children 5-10 years of age: half a tablet up to three times daily. Avil tablets are not recommended in children under 5 years of age.
Route of Administration: Oral
Histamine (100 uM)-induced contractions was blocked by pheniramine (0.32 uM) by 74% in neonatal small intestinal smooth muscle of dilated pre-atretic part of intestinal atresia.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:13:39 UTC 2023
Edited
by admin
on Fri Dec 15 15:13:39 UTC 2023
Record UNII
NYW905655B
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PHENIRAMINE MALEATE
EP   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN  
Official Name English
2-(.ALPHA.-(2-DIMETHYLAMINOETHYL)BENZYL)PYRIDINE BIMALEATE
Common Name English
PHENIRAMINE MALEATE [VANDF]
Common Name English
PHENIRAMINE MALEATE COMPONENT OF NAPHCON-A
Common Name English
PM-241
Code English
NAPHCON A
Brand Name English
PHENIRAMINE MALEATE [USP-RS]
Common Name English
2-(.ALPHA.-(2-(DIMETHYLAMINO)ETHYL)BENZYL)PYRIDINE BIMALEATE
Common Name English
ANTOLOZINE
Brand Name English
PHENIRAMINE MALEATE [USP MONOGRAPH]
Common Name English
Pheniramine maleate [WHO-DD]
Common Name English
VISINE-A COMPONENT PHENIRAMINE MALEATE
Common Name English
NAPHCON-A COMPONENT PHENIRAMINE MALEATE
Common Name English
PHENIRAMINE MALEATE [JAN]
Common Name English
PHENIRAMINE MALEATE COMPONENT OF VISINE-A
Common Name English
FERVEX
Brand Name English
PHENIRAMINE MALEATE [USAN]
Common Name English
N,N-Dimethyl-3-phenyl-3-(2-pyridyl)propylamine hydrogen maleate
Systematic Name English
1-PHENYL-1-(2-PYRIDYL)-3-DIMETHYLAMINOPROPANE MALEATE
Systematic Name English
PHENIRAMINE MALEATE [EP MONOGRAPH]
Common Name English
INHISTON
Brand Name English
2-PYRIDINEPROPANAMINE, N,N-DIMETHYL-.GAMMA.-PHENYL-, (Z)-2-BUTENEDIOATE (1:1)
Systematic Name English
2-PYRIDINEPROPANAMINE, N,N-DIMETHYL-.GAMMA.-PHENYL-, (2Z)-2-BUTENEDIOATE (1:1)
Systematic Name English
1-PHENYL-1-(2-PYRIDYL)-3-DIMETHAMINOPROPANE MALEINATE
Common Name English
DANERAL
Brand Name English
TRIMETOSE
Brand Name English
NSC-757270
Code English
PROPHENPYRIDAMINE MALEATE
Common Name English
PHENIRAMINE MALEATE COMPONENT OF OPCON-A
Common Name English
TRIMETON
Brand Name English
PYRIDINE, 2-(.ALPHA.-(2-(DIMETHYLAMINO)ETHYL)BENZYL)-, MALEATE (1:1)
Systematic Name English
PHENIRAMINE MALEATE [EP IMPURITY]
Common Name English
PHENIRAMINE HYDROGEN MALEATE
Common Name English
PHENIRAMINE MALEATE [MI]
Common Name English
PHENIRAMINE MALEATE [MART.]
Common Name English
AVIL
Brand Name English
PHENIRAMINE MALEATE [ORANGE BOOK]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29578
Created by admin on Fri Dec 15 15:13:39 UTC 2023 , Edited by admin on Fri Dec 15 15:13:39 UTC 2023
CFR 21 CFR 341.12
Created by admin on Fri Dec 15 15:13:39 UTC 2023 , Edited by admin on Fri Dec 15 15:13:39 UTC 2023
Code System Code Type Description
MERCK INDEX
m8619
Created by admin on Fri Dec 15 15:13:39 UTC 2023 , Edited by admin on Fri Dec 15 15:13:39 UTC 2023
PRIMARY Merck Index
CAS
132-20-7
Created by admin on Fri Dec 15 15:13:39 UTC 2023 , Edited by admin on Fri Dec 15 15:13:39 UTC 2023
PRIMARY
DRUG BANK
DBSALT001440
Created by admin on Fri Dec 15 15:13:39 UTC 2023 , Edited by admin on Fri Dec 15 15:13:39 UTC 2023
PRIMARY
EPA CompTox
DTXSID0025866
Created by admin on Fri Dec 15 15:13:39 UTC 2023 , Edited by admin on Fri Dec 15 15:13:39 UTC 2023
PRIMARY
ECHA (EC/EINECS)
205-051-4
Created by admin on Fri Dec 15 15:13:39 UTC 2023 , Edited by admin on Fri Dec 15 15:13:39 UTC 2023
PRIMARY
FDA UNII
NYW905655B
Created by admin on Fri Dec 15 15:13:39 UTC 2023 , Edited by admin on Fri Dec 15 15:13:39 UTC 2023
PRIMARY
RXCUI
266959
Created by admin on Fri Dec 15 15:13:39 UTC 2023 , Edited by admin on Fri Dec 15 15:13:39 UTC 2023
PRIMARY RxNorm
RS_ITEM_NUM
1522301
Created by admin on Fri Dec 15 15:13:39 UTC 2023 , Edited by admin on Fri Dec 15 15:13:39 UTC 2023
PRIMARY
CAS
155683-11-7
Created by admin on Fri Dec 15 15:13:39 UTC 2023 , Edited by admin on Fri Dec 15 15:13:39 UTC 2023
SUPERSEDED
DAILYMED
NYW905655B
Created by admin on Fri Dec 15 15:13:39 UTC 2023 , Edited by admin on Fri Dec 15 15:13:39 UTC 2023
PRIMARY
EVMPD
SUB03747MIG
Created by admin on Fri Dec 15 15:13:39 UTC 2023 , Edited by admin on Fri Dec 15 15:13:39 UTC 2023
PRIMARY
NCI_THESAURUS
C29358
Created by admin on Fri Dec 15 15:13:39 UTC 2023 , Edited by admin on Fri Dec 15 15:13:39 UTC 2023
PRIMARY
SMS_ID
100000090467
Created by admin on Fri Dec 15 15:13:39 UTC 2023 , Edited by admin on Fri Dec 15 15:13:39 UTC 2023
PRIMARY
NSC
757270
Created by admin on Fri Dec 15 15:13:39 UTC 2023 , Edited by admin on Fri Dec 15 15:13:39 UTC 2023
PRIMARY
ChEMBL
CHEMBL1193
Created by admin on Fri Dec 15 15:13:39 UTC 2023 , Edited by admin on Fri Dec 15 15:13:39 UTC 2023
PRIMARY
PUBCHEM
5282139
Created by admin on Fri Dec 15 15:13:39 UTC 2023 , Edited by admin on Fri Dec 15 15:13:39 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY